Arcus Biosciences Inc (RCUS)
15.56
+0.06
(+0.39%)
USD |
NYSE |
Nov 04, 16:00
15.55
-0.01
(-0.06%)
After-Hours: 20:00
Arcus Biosciences Enterprise Value: 453.61M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 453.61M |
| November 01, 2024 | 448.13M |
| October 31, 2024 | 429.84M |
| October 30, 2024 | 493.84M |
| October 29, 2024 | 531.33M |
| October 28, 2024 | 554.18M |
| October 25, 2024 | 523.10M |
| October 24, 2024 | 661.15M |
| October 23, 2024 | 615.44M |
| October 22, 2024 | 566.98M |
| October 21, 2024 | 582.52M |
| October 18, 2024 | 716.92M |
| October 17, 2024 | 698.64M |
| October 16, 2024 | 663.90M |
| October 15, 2024 | 656.58M |
| October 14, 2024 | 684.92M |
| October 11, 2024 | 710.52M |
| October 10, 2024 | 594.41M |
| October 09, 2024 | 652.92M |
| October 08, 2024 | 628.24M |
| October 07, 2024 | 612.70M |
| October 04, 2024 | 553.27M |
| October 03, 2024 | 430.76M |
| October 02, 2024 | 438.07M |
| October 01, 2024 | 440.81M |
| Date | Value |
|---|---|
| September 30, 2024 | 428.93M |
| September 27, 2024 | 439.90M |
| September 26, 2024 | 438.07M |
| September 25, 2024 | 427.10M |
| September 24, 2024 | 457.27M |
| September 23, 2024 | 467.33M |
| September 20, 2024 | 537.73M |
| September 19, 2024 | 566.98M |
| September 18, 2024 | 538.64M |
| September 17, 2024 | 560.58M |
| September 16, 2024 | 576.12M |
| September 13, 2024 | 672.12M |
| September 12, 2024 | 620.92M |
| September 11, 2024 | 582.52M |
| September 10, 2024 | 556.01M |
| September 09, 2024 | 522.18M |
| September 06, 2024 | 468.24M |
| September 05, 2024 | 507.55M |
| September 04, 2024 | 523.10M |
| September 03, 2024 | 545.95M |
| August 30, 2024 | 596.24M |
| August 29, 2024 | 615.44M |
| August 28, 2024 | 609.04M |
| August 27, 2024 | 630.07M |
| August 26, 2024 | 670.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.18M
Minimum
May 11 2022
2.880B
Maximum
Nov 23 2021
886.37M
Average
683.05M
Median
Dec 31 2023
Enterprise Value Benchmarks
| Merck & Co Inc | 284.72B |
| Intra-Cellular Therapies Inc | 8.129B |
| Syndax Pharmaceuticals Inc | 1.179B |
| Clearside Biomedical Inc | 48.00M |
| Janux Therapeutics Inc | 2.264B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -93.00M |
| Revenue (Quarterly) | 39.00M |
| Total Expenses (Quarterly) | 145.00M |
| EPS Diluted (Quarterly) | -1.02 |
| Profit Margin (Quarterly) | -238.5% |
| Earnings Yield | -19.86% |
| Normalized Earnings Yield | -18.37 |